These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28665377)

  • 1. [The novel approaches to the rehabilitation of the patients presenting with gastroesophageal reflux disease and co-morbid pathology].
    Komleva NE; Marjanovsky AA; Danilov AN; Agasarov LG
    Vopr Kurortol Fizioter Lech Fiz Kult; 2017; 94(2):20-23. PubMed ID: 28665377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastroesophageal reflux disease.
    Pettit M
    Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathophysiology and treatment of non-erosive reflux disease].
    Oshima T; Miwa H
    Nihon Shokakibyo Gakkai Zasshi; 2009 Mar; 106(3):327-34. PubMed ID: 19262046
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
    Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
    J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived health state utilities for gastroesophageal reflux disease.
    Gerson LB; Ullah N; Hastie T; Triadafilopoulos G; Goldstein M
    Am J Gastroenterol; 2005 Mar; 100(3):524-33. PubMed ID: 15743346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.
    Bautista JM; Wong WM; Pulliam G; Esquivel RF; Fass R
    Dig Dis Sci; 2005 Oct; 50(10):1909-15. PubMed ID: 16187196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroesophageal reflux disease: pathophysiology and pharmacology overview.
    Dajani EZ
    J Assoc Acad Minor Phys; 2000; 11(1):7-11. PubMed ID: 10826019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain.
    He S; Liu Y; Chen Y; Tang Y; Xu J; Tang C
    Dis Esophagus; 2016 May; 29(4):367-76. PubMed ID: 25721424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of symptoms and use of medication for gastroesophageal reflux in an Australian community.
    Watson DI; Lally CJ
    World J Surg; 2009 Jan; 33(1):88-94. PubMed ID: 18949510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and management of laryngopharyngeal reflux.
    Ford CN
    JAMA; 2005 Sep; 294(12):1534-40. PubMed ID: 16189367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacologic approaches in gastroesophageal reflux disease.
    Armstrong D; Sifrim D
    Gastroenterol Clin North Am; 2010 Sep; 39(3):393-418. PubMed ID: 20951909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
    Takenaka R; Okada H; Kawano S; Komazawa Y; Yoshinaga F; Nagata S; Inoue M; Komatsu H; Onogawa S; Kushiyama Y; Mukai S; Todo H; Okanobu H; Manabe N; Tanaka S; Haruma K; Kinoshita Y
    World J Gastroenterol; 2016 Jun; 22(23):5430-5. PubMed ID: 27340360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.